Ken Griffin Acadia Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 89,700 shares of ACAD stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,700

Previous 81,300 10.33%

Holding current value

$1.47 Million

Previous $1.5 Million 3.06%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $1.24 Million - $1.56 Million	84,510 Added 14.85%	653,768 $10.6 Million
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $7.4 Million - $12.8 Million	416,224 Added 271.98%	569,258 $10.5 Million
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $3.07 Million - $4.69 Million	147,625 Added 2729.25%	153,034 $4.79 Million
Q3 2023 Nov 14, 2023	SELL	$20.84 - $33.47 $370,785 - $595,498	-17,792 Reduced 76.69%	5,409 $112,000
Q2 2023 Aug 14, 2023	SELL	$17.8 - $25.65 $1.43 Million - $2.06 Million	-80,482 Reduced 77.62%	23,201 $555,000
Q1 2023 May 15, 2023	SELL	$16.32 - $20.92 $1.89 Million - $2.43 Million	-116,075 Reduced 52.82%	103,683 $1.95 Million
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $2.69 Million - $3.53 Million	-189,521 Reduced 46.31%	219,758 $3.5 Million
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $1.55 Million - $2.01 Million	109,982 Added 36.75%	409,279 $6.7 Million
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $1.53 Million - $3.2 Million	-117,641 Reduced 28.22%	299,297 $4.22 Million
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $3.73 Million - $4.9 Million	178,263 Added 74.69%	416,938 $10.1 Million
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $9.16 Million - $14.8 Million	-545,416 Reduced 69.56%	238,675 $0
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $10.3 Million - $16.1 Million	650,085 Added 485.12%	784,091 $13 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $1.84 Million - $2.61 Million	-95,048 Reduced 41.5%	134,006 $0
Q1 2021 May 17, 2021	SELL	$25.02 - $54.99 $26.1 Million - $57.4 Million	-1,043,975 Reduced 82.01%	229,054 $5.91 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $53.2 Million - $73.6 Million	-1,296,722 Reduced 50.46%	1,273,029 $68.1 Million
Q3 2020 Nov 16, 2020	SELL	$36.42 - $57.0 $47.2 Million - $73.9 Million	-1,296,132 Reduced 33.53%	2,569,751 $106 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $6.46 Million - $8.68 Million	164,528 Added 4.45%	3,865,883 $187 Million
Q1 2020 May 15, 2020	BUY	$31.65 - $46.87 $34.1 Million - $50.5 Million	1,076,658 Added 41.02%	3,701,355 $156 Million
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $25.7 Million - $36.5 Million	710,106 Added 37.09%	2,624,697 $112 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $3.35 Million - $6.64 Million	150,837 Added 8.55%	1,914,591 $0
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $293,505 - $353,918	-12,586 Reduced 0.71%	1,763,754 $47.1 Million
Q1 2019 May 15, 2019	SELL	$16.17 - $27.38 $17.2 Million - $29.1 Million	-1,062,582 Reduced 37.43%	1,776,340 $0
Q4 2018 Feb 14, 2019	BUY	$14.32 - $22.92 $5.15 Million - $8.24 Million	359,302 Added 14.49%	2,838,922 $0
Q3 2018 Nov 13, 2018	BUY	$13.03 - $21.81 $31.1 Million - $52.1 Million	2,389,582 Added 2653.97%	2,479,620 $0
Q2 2018 Aug 10, 2018	BUY	$15.07 - $22.34 $737,797 - $1.09 Million	48,958 Added 119.18%	90,038 $0
Q1 2018 May 11, 2018	SELL	$22.47 - $32.33 $842,894 - $1.21 Million	-37,512 Reduced 47.73%	41,080 $923,000
Q4 2017 Feb 09, 2018	BUY	$26.84 - $39.14 $37,039 - $54,013	1,380 Added 1.79%	78,592 $2.37 Million
Q3 2017 Nov 09, 2017	BUY	$29.49 - $38.37 $2.28 Million - $2.96 Million	77,212	77,212 $2.91 Million

Others Institutions Holding ACAD

# of Institutions

288

Shares Held

161M

Call Options Held

723K

Put Options Held

257K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account